Detection of Resistance to Therapy in Hematolymphoid Neoplasms

  • Karen Weck
Part of the Molecular Pathology Library book series (MPLB, volume 4)


In the past several decades, treatment of hematolymphoid disorders has made dramatic strides. However, the presence or development of resistance to various chemotherapeutic agents is an important problem that affects response to therapy. Drug resistance can be either intrinsic to cancer cells or acquired while on therapy. In this chapter, the major molecular mechanisms of resistance to therapy in hematolymphoid disorders are discussed and techniques that are used to detect resistance to therapy are described. General markers of resistance to therapy, such as cytogenetic markers of resistance or functional assays to measure response to therapy, are not described in this chapter. Rather, this chapter focuses on the detection of specific molecular mechanisms of drug resistance due to the presence or alteration of a specific gene product.


Chronic Myeloid Leukemia Resistance Mutation Imatinib Mesylate Internal Tandem Duplication MDR1 Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    O’Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242–2249.CrossRefPubMedGoogle Scholar
  2. 2.
    Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727–734.CrossRefPubMedGoogle Scholar
  3. 3.
    Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008;113:985–994.CrossRefPubMedGoogle Scholar
  4. 4.
    Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117:2562–2569.CrossRefPubMedGoogle Scholar
  5. 5.
    Hochaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321–1331.CrossRefGoogle Scholar
  6. 6.
    Cowan-Jacob SW, Gues V, Fendrich G, et al. Imatnib (STI-571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem. 2004;4:285–299.CrossRefPubMedGoogle Scholar
  7. 7.
    Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI-571 in chronic myeloid leukemia. Curr Opin Hematol. 2002;9:303–307.CrossRefPubMedGoogle Scholar
  8. 8.
    Apperley JH. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018–1029.CrossRefPubMedGoogle Scholar
  9. 9.
    O’Hare T, Eide CA, Tyner JW. SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci USA. 2008;14:5507–5512.CrossRefGoogle Scholar
  10. 10.
    Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther. 2008;8:1387–1398.CrossRefPubMedGoogle Scholar
  11. 11.
    O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–4505.CrossRefPubMedGoogle Scholar
  12. 12.
    Bradeen HA, Eide CA, O’Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108:2332–2338.CrossRefPubMedGoogle Scholar
  13. 13.
    Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA. 2005;102:3395–3400.CrossRefPubMedGoogle Scholar
  14. 14.
    Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006;66:1007–1014.CrossRefPubMedGoogle Scholar
  15. 15.
    Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood. 2007;109:5011–5015.CrossRefPubMedGoogle Scholar
  16. 16.
    von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006;108:1328–1333.CrossRefGoogle Scholar
  17. 17.
    Soverini S, Martnelli G, Colarossi S, et al. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in PH+ ALL. Lancet Oncol. 2007;8:1809–1820.CrossRefGoogle Scholar
  18. 18.
    Cortes J, Jabbour E, Knatarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007;110:4005–4011.CrossRefPubMedGoogle Scholar
  19. 19.
    Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005;106(6):2128–2137.CrossRefPubMedGoogle Scholar
  20. 20.
    Sherbenou DW, Wong MJ, Humayun A, et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia. 2007;21(3):489–493.CrossRefPubMedGoogle Scholar
  21. 21.
    Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.CrossRefPubMedGoogle Scholar
  22. 22.
    Vivante A, Amariglio N, Koren-Michowitz M, et al. High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations. Leukemia. 2007;21:1318–1321.CrossRefPubMedGoogle Scholar
  23. 23.
    Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007;109:500–502.CrossRefPubMedGoogle Scholar
  24. 24.
    Nardi V, Raz T, Cao X, et al. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008;27:775–782.CrossRefPubMedGoogle Scholar
  25. 25.
    Oehler VG, Qin J, Ramakrishnan R, et al. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia. 2008 Jul 10 [Epub ahead of print].Google Scholar
  26. 26.
    Transgenomic’s WAVE System used for the early detection of drug resistance mutations in chronic myeloid leukemia. Pharmaco­genomics. 2005;6:458–459.Google Scholar
  27. 27.
    Ernst T, Erben P, Muller MC, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica. 2008;93:186–192.CrossRefPubMedGoogle Scholar
  28. 28.
    O’Hare T, Eide CA, Deininger MW. Persistent LYN signaling in imatinib-resistant, BCR-ABL–independent chronic myelogenous leukemia. J Natl Cancer Inst. 2008;100:908–909.PubMedGoogle Scholar
  29. 29.
    Wu J, Meng F, Kong L-Y, et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst. 2008;100:927–940.Google Scholar
  30. 30.
    Wu J, Meng F, Lu H, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistance chronic myelogenous leukemia cells. Blood. 2008;111:3821–3829.CrossRefPubMedGoogle Scholar
  31. 31.
    Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690–698.CrossRefPubMedGoogle Scholar
  32. 32.
    Dai Y, Rahmani M, Corey SJ, et al. Bcr-Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem. 2004;279:34227–34239.CrossRefPubMedGoogle Scholar
  33. 33.
    Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol. 2006;57:145–164.CrossRefPubMedGoogle Scholar
  34. 34.
    Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 2008 May 29 [Epub ahead of print].Google Scholar
  35. 35.
    Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26(12):2046–2051.CrossRefPubMedGoogle Scholar
  36. 36.
    Curtin J, Busam K, Pinkel D, et al. Somatic Activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–4346.CrossRefPubMedGoogle Scholar
  37. 37.
    Antonescu DR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer. 2007;121:257–264.CrossRefPubMedGoogle Scholar
  38. 38.
    Hornick JL, Fletcher CDM. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol. 2007;38:679–687.CrossRefPubMedGoogle Scholar
  39. 39.
    Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev. 2007;17:3–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignanceis. Nat Rev Cancer. 2003;3:650–665.CrossRefPubMedGoogle Scholar
  41. 41.
    Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. Br J Haematol. 2003;122:523–538.CrossRefPubMedGoogle Scholar
  42. 42.
    Lin P, Jones D, Medeiros J, et al. Activating FLT3 mutations are detectable in chronic and blast phases of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol. 2006;126:530–533.CrossRefPubMedGoogle Scholar
  43. 43.
    Kottardis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–1759.CrossRefGoogle Scholar
  44. 44.
    Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication on mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776–2784.CrossRefPubMedGoogle Scholar
  45. 45.
    Illmer T, Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clin Lymphoma Myeloma. 2007;8:S24–S34.CrossRefPubMedGoogle Scholar
  46. 46.
    Tam WF, Gilliland GD. Can FLT3 inhibitors overcome resistance in AML? Best Pract Res Clin Haematol. 2008;21:13–20.CrossRefPubMedGoogle Scholar
  47. 47.
    Clark JJ, Coold J, Curley DP, et al. Variable sensitivity of FLT3 activation loop mutations to the small molecular tyrosine kinase inhibitor MLN518. Blood. 2004;104:2867–2872.CrossRefPubMedGoogle Scholar
  48. 48.
    Cools J, Mentens N, Furet P, et al. Prediction of resistance to small molecular FLT3 inhibitors: implications for molecularly targeted thearpy of acute leukemia. Cancer Res. 2004;64:6385–6389.CrossRefPubMedGoogle Scholar
  49. 49.
    Heidel F, Solem FK, Breitenbuecher F, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006;107:293–300.CrossRefPubMedGoogle Scholar
  50. 50.
    Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105–127.CrossRefPubMedGoogle Scholar
  51. 51.
    Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991;66:85–94.CrossRefPubMedGoogle Scholar
  52. 52.
    Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein, in human peripheral blood lymphocytes. Blood. 1992;80:2735–2739.PubMedGoogle Scholar
  53. 53.
    Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multi-drug resistant phenotype. Blood. 1992;80:2729–2734.PubMedGoogle Scholar
  54. 54.
    Mari JP, Brophy NA, Ehsan MN, et al. Expression of multi-drug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. Br J Haematol. 1992;81:145–152.CrossRefGoogle Scholar
  55. 55.
    Polgar O, Bates SE. ABC transporters in the balance: is there a role in multidrug resistance? Biochem Soc Trans. 2005;33:241–245.PubMedGoogle Scholar
  56. 56.
    Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the hydra? Leukemia. 2007;21:1172–1176.CrossRefPubMedGoogle Scholar
  57. 57.
    Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol. 1994;12:2453–2459.PubMedGoogle Scholar
  58. 58.
    Chauncey TR. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol. 2001;13:21–26.CrossRefPubMedGoogle Scholar
  59. 59.
    Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18:401–408.CrossRefPubMedGoogle Scholar
  60. 60.
    Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739–3745.CrossRefPubMedGoogle Scholar
  61. 61.
    Stromskaya TP, Rybalkina EY, Kruglov SS, et al. Role of p-glycoprotein in evolution of populations of CML cells treated with imatinib. Biochemistry (Mosc). 2008;73:29–37.Google Scholar
  62. 62.
    Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-gycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations. Cancer Res. 1996;56:3010–3020.PubMedGoogle Scholar
  63. 63.
    Leith CP, Kopecky KJ, Chen I-M, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. Blood. 1999;94:1086–1099.PubMedGoogle Scholar
  64. 64.
    Legrand O, Simonin G, Beauchap-Nicoud A, et al. Simultaneous activity of MRP1 and P-gp is correlated with in vitro resistance to daunorubucin and with in vivo resistance in adult acute myloid leukemia. Blood. 1999;94:1046–1056.PubMedGoogle Scholar
  65. 65.
    Legrand O, Simonin G, Zittoun R, et al. Lung resistance protein (LRP) gene expression in adult acute myleoid leukemia: a critical evaluation by three techniques. Leukemia. 1998;12:1367–1374.CrossRefPubMedGoogle Scholar
  66. 66.
    Valera ET, Scrideli CA, Queiroz RG, Mori BM, Tone LG. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J. 2004;122:166–171.CrossRefPubMedGoogle Scholar
  67. 67.
    Kudoh D, Ramanna M, Ravatn R, et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 2000;60:4161–4166.PubMedGoogle Scholar
  68. 68.
    Stegmann AP, Honders MW, Hagemeijer A, et al. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2’-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann Hematol. 1995;71:41–47.CrossRefPubMedGoogle Scholar
  69. 69.
    Hubeek I, Peters GJ, Broekhuizen AJ, et al. Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity. Nucleosides Nucleotides Nucleic Acids. 2004;23:1351–1356.CrossRefPubMedGoogle Scholar
  70. 70.
    Jankovicová K, Krejsek J, Kopecký O, et al. The multidrug resistance and apoptosis evaluation in acute myeloid leukemia cells after the in vitro doxorubicin treatment. Acta Medica (Hradec Kralove). 2004;47:181–185.Google Scholar
  71. 71.
    van Stijn A, Kok A, van der Pol MA, et al. A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia. Leukemia. 2003;17:780–786.CrossRefPubMedGoogle Scholar
  72. 72.
    Srinivas G, Kusumakumary P, Nair MK, et al. Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leukaemia. J Cancer Res Clin Oncol. 2000;126:62–67.CrossRefPubMedGoogle Scholar
  73. 73.
    Lacombe F, Belloc F, Dumain P, et al. Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry. Blood. 1994;84:716–723.PubMedGoogle Scholar
  74. 74.
    Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica. 2007;92(1):81–94.CrossRefPubMedGoogle Scholar
  75. 75.
    Song JH, Choi CH, Yeom HJ, et al. Monitoring the gene expression profiles of doxorubicin-resistant acute myelocytic leukemia cells by DNA microarray analysis. Life Sci. 2006;79:193–202.CrossRefPubMedGoogle Scholar
  76. 76.
    Ichikawa Y, Hirokawa M, Aiba N, et al. Monitoring the expression profiles of doxorubicin-resistant K562 human leukemia cells by serial analysis of gene expression. Int J Hematol. 2004;79:276–282.CrossRefPubMedGoogle Scholar
  77. 77.
    Gillet JP, Efferth T, Steinbach D, et al. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res. 2004;64:8987–8993.CrossRefPubMedGoogle Scholar
  78. 78.
    Gao K, Lockwood WW, Li J, et al. Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells. Int J Oncol. 2008;32:1343–1349.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Karen Weck
    • 1
  1. 1.Departments of Pathology and Laboratory Medicine and GeneticsUniversity of North CarolinaChapel HillUSA

Personalised recommendations